Cargando…

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Immune-evasion and immune checkpoints are promising new therapeutic targets for several cancer entities. In ovarian cancer, the clinical role of programmed cell death receptor ligand 1 (PD-L1) expression as mechanism to escape immune recognition has not been clarified yet. We analyzed PD-L1 expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aust, Stefanie, Felix, Sophie, Auer, Katharina, Bachmayr-Heyda, Anna, Kenner, Lukas, Dekan, Sabine, Meier, Samuel M., Gerner, Christopher, Grimm, Christoph, Pils, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339797/ https://www.ncbi.nlm.nih.gov/pubmed/28266500 http://dx.doi.org/10.1038/srep42929

Ejemplares similares

Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
por: Auer, Katharina, et al.
Publicado: (2016)

Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2016)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types
por: Pils, Dietmar, et al.
Publicado: (2020)

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?
por: Sukhbaatar, Nyamdelger, et al.
Publicado: (2017)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs
por: Reiner, Agnes T., et al.
Publicado: (2017)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach
por: Bekos, Christine, et al.
Publicado: (2019)

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance
por: Zhang, Tao, et al.
Publicado: (2021)

Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2015)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

PD-L1 Expression in Mastocytosis
por: Williams, Margaret, et al.
Publicado: (2019)

PD-L1: expression regulation
por: Zhou, Yu-Jie, et al.
Publicado: (2023)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
por: Johnson, Douglas B., et al.
Publicado: (2016)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

PD-1/PD-L1 expression in anal squamous intraepithelial lesions
por: Bucau, Margot, et al.
Publicado: (2020)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
por: Heiland, Dieter Henrik, et al.
Publicado: (2017)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Glial Cell Expression of PD-L1
por: Chauhan, Priyanka, et al.
Publicado: (2019)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
por: Morales-Betanzos, Carlos A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3c0drrn0nlpfpahnkoba00q8gi